Effect of Limosilactobacillus reuteri Probiotic on Oral Mucositis in Patients Undergoing Head and Neck Radiation: A Randomised Trial
Oral Diseases · 2026-02 · 32 (2) · 480-491
DOI: 10.1111/odi.70083 ↗At a glance
Randomisierte kontrollierte Studie in Oral Diseases, published online on 2025-08-31. Written by Charlene Enhui Goh and 7 co-authors. Institution: Faculty of Dentistry, National University of Singapore, Singapore City, Singapore. Major MEDLINE topics: Probiotics, Limosilactobacillus reuteri, Stomatitis, Head and Neck Neoplasms. Cited 7 times so far (Crossref); 61 references. Funded by: National University Health System, Ministry of Education - Singapore, Pharmaforte Singapore Pte. Ltd..
Abstract (original language)
Objective
Limited management strategies exist for cancer therapy‐induced oral mucositis (OM). Materials and Methods We conducted a randomised, double‐blind, placebo‐controlled trial to assess the efficacy and safety of Limosilactobacillus reuteri (LR) probiotic to prevent and reduce the severity of OM in head and neck cancer patients undergoing radiotherapy (RT). Patients ≥ 21 years requiring head and neck RT of ≥ 60 Gy and those undergoing concurrent chemotherapy with RT (CCRT) with no prior OM were recruited. OM incidence and severity were assessed weekly from baseline to two weeks post‐RT. Oral samples were collected at baseline and study mid‐point to profile microbiome changes.
Results
Overall, no significant differences in OM incidence or severity (grade ≥ 3) were observed between LR and placebo groups. However, subgroup analyses of participants who received RT‐only showed significantly lower mean OM scores (−0.42; 95% CI: −0.75, −0.09; p = 0.02) over time in the LR probiotic group. Beta diversity of the oral microbiome was significantly different between the RT‐only probiotic and placebo groups (PERMANOVA: F = 1.77; R 2 = 0.07; p = 0.025). No serious adverse effects were observed in the LR group.
Conclusion
LR probiotic use was safe and associated with a reduced OM incidence and severity in RT‐only participants. These findings are promising and provide important insights for future studies in larger cohorts. Trial Registration ClinicalTrials.gov : NCT03552458
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Faculty of Dentistry, National University of Singapore, Singapore City, Singapore.
- Singapore Centre for Environmental Life Sciences Engineering, National University of Singapore, Singapore, Singapore.
- Department of Radiation Oncology, National University Cancer Institute, Singapore City, Singapore.
ORCID profiles: Charlene Enhui Goh, Nitasha Gupta, Kai Soo Tan
Funding
- National University Health System
- Ministry of Education - Singapore
- Pharmaforte Singapore Pte. Ltd.
Cite
APA
Goh, C. E., Williams, R., Gupta, N., Ho, F., Islam, I., Lai, C. W. M., Tan, K. S., & Hong, C. H. L. (2026). Effect of Limosilactobacillus reuteri Probiotic on Oral Mucositis in Patients Undergoing Head and Neck Radiation: A Randomised Trial. Oral Diseases, 32(2), 480-491. https://doi.org/10.1111/odi.70083
Vancouver
Goh CE, Williams R, Gupta N, Ho F, Islam I, Lai CWM, et al. Effect of Limosilactobacillus reuteri Probiotic on Oral Mucositis in Patients Undergoing Head and Neck Radiation: A Randomised Trial. Oral Diseases. 2026;32(2):480-491. doi:10.1111/odi.70083
BibTeX
@article{Goh2026,
author = {Goh, Charlene Enhui and Williams, Rohan and Gupta, Nitasha and Ho, Francis and Islam, Intekhab and Lai, Clement Wei Ming and Tan, Kai Soo and Hong, Catherine Hsu Ling},
title = {Effect of Limosilactobacillus reuteri Probiotic on Oral Mucositis in Patients Undergoing Head and Neck Radiation: A Randomised Trial},
journal = {Oral Diseases},
year = {2026},
volume = {32},
number = {2},
pages = {480--491},
doi = {10.1111/odi.70083}
}
EUVIMED